Project Grant R01GM152463
- This $462,000 Project Grant award from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training program (CFDA 93.859), supports research to establish the epigenetic mechanisms that govern embryonic stem cell (ESC) biology. The research aims to define how ESC gene expression programs and biology are regulated by DNA methylation and the TET family of DNA demethylases. Key objectives include: Dissecting the molecular and biological requirements...
- This Project Grant award of $950,000.00 from the National Science Foundation's Biological Sciences (CFDA 47.074) program supports research to investigate how the enzyme thymine DNA glycosylase (TDG) is regulated and targeted throughout the genome to maintain proper DNA methylation patterns. The research aims to improve understanding of how DNA methylation landscapes are established and maintained under both normal and disease conditions, which could lead to future clinical applications. The...
- This Project Grant award from the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) provides $1,602,000.00 to The Children's Hospital of Philadelphia Research Institute to develop and optimize a new class of Epigenetic Reprogramming Factors (ERFs) that can target hundreds, thousands, or tens of thousands of DNA regions in a pathway-specific manner. The goal is to leverage this ERF technology to prevent or reverse epigenetic signatures associated...
- This Project Grant award from the National Institute of Environmental Health Sciences (NIEHS), under the Environmental Health federal grant program (CFDA 93.113), provides $127,384 to the University of Pittsburgh to research the dynamics of oxidative DNA demethylation and the impact of chromatin on this process. The key objectives of the research are to: 1) determine the dynamics of the enzyme thymine DNA glycosylase (TDG) as it diffuses and binds to chromatin in living cells, and its binding to...
- This federal Project Grant award of $641,794 was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant aims to elucidate the mechanisms that protect beta-cells from DNA damage during periods of growth and adaptation, in order to maintain beta-cell homeostasis and prevent the loss of functional beta-cells, a key factor in the development of type 1 and type 2...
- This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower program) provides $144,981 to the University of California, San Diego (UC San Diego) to characterize the role of extrachromosomal DNA (ecDNA) in shaping the heterogeneity and plasticity of glioblastoma (GBM) cellular states. The award period runs from September 3, 2025 to August 31, 2027. The project aims to determine how ecDNA, which are large circular DNA elements harboring oncogenes,...
- This $1,737,000 Project Grant awarded by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) supports the development of innovative single-cell genomics technologies for joint analysis of regulatory dynamics and transcriptional states. Key objectives include: Developing multiomics tools to measure rates of epigenomic changes (DNA methylation, demethylation, oxidative damage, DNA repair) and relate these to...
- This federal Project Grant award for $378,123 from the National Institute of Child Health and Human Development (NICHD) under the Child Health and Human Development Extramural Research program (CFDA 93.865) supports research to identify and test mechanisms that establish transcriptional regulatory potency in early embryos. The primary activities include using genomic methods like PRO-seq, DREG, and OMNI-ATAC to characterize transcriptionally active regulatory elements, DNA accessibility, and...
- This Project Grant award of $1,399,500.00 from the National Institutes of Health (NIH) Trans-NIH Research Support program (CFDA 93.310) supports time-lapse epigenome profiling research at The Washington University in Missouri. The goal is to observe spatiotemporal changes in chromatin-mediated gene regulation that are associated with successful cellular reprogramming, and to functionally test whether these epigenetic events can lead to more efficient induced cell fate conversion outcomes. The...
- This federal Project Grant award of $390,000.00 from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training program (CFDA 93.859), supports research to elucidate the mechanisms underlying DNA double-strand break repair at Thomas Jefferson University, doing business as Sidney Kimmel Medical College. The research aims to determine the regulatory mechanisms of the multi-protein and multi-step process required to coordinate the repair of DNA...
OVERCOMING EPIGENETIC BARRIERS TO SOMATIC CELL REPROGRAMMING BY THE XPC DNA REPAIR COMPLEX - PROJECT SUMMARY/ABSTRACT. THYMINE DNA GLYCOSYLASE (TDG) IS A KEY ENZYME IN SOMATIC CELL REPROGRAMMING. TDG CATALYZES DNA DEMETHYLATION AND REACTIVATION OF SPECIFIC SETS OF GENES TO INDUCE A PLURIPOTENT CELL FATE IN SOMATIC CELLS. HOWEVER, THERE IS A FUNDAMENTAL LACK OF UNDERSTANDING OF HOW TDG IS DIRECTED TO ITS TARGET GENES TO CATALYZE DYNAMIC DEMETHYLATION TO FACILITATE THEIR TIMELY ACTIVATION AND THEREBY CELL FATE CONVERSION. THUS, OUR UNDERSTANDING OF EPIGENETIC MECHANISMS OF CELL FATE CHANGE REMAINS INCOMPLETE. THE LONG-TERM GOAL IS TO UNDERSTAND FUNDAMENTAL MECHANISMS BY WHICH FACTORS SUCH AS TDG CONTROL PROCESSES REQUIRING WIDESPREAD EPIGENETIC CHANGES, INCLUDING NORMAL EMBRYONIC DEVELOPMENT AND SOMATIC CELL REPROGRAMMING. OUR RECENT STUDIES HAVE IDENTIFIED THE NUCLEOTIDE EXCISION REPAIR PROTEIN XPC AS A POTENT ACTIVATOR OF TDG-DEPENDENT DNA DEMETHYLATION GENOME-WIDE AND PREFERENTIALLY AT GENE ENHANCERS BOUND BY TRANSCRIPTION FACTOR HIF1A. THE OVERALL OBJECTIVE OF THIS PROJECT IS TO DETERMINE HOW XPC AND TDG TOGETHER INTEGRATE SIGNALS TO REGULATE ACTIVE DNA DEMETHYLATION AND EPIGENETIC REPROGRAMMING. THE CENTRAL HYPOTHESIS IS THAT XPC IS A NOVEL REGULATOR OF DYNAMIC DNA DEMETHYLATION VIA TDG AND THEREBY PLAYS AN ESSENTIAL ROLE IN PLURIPOTENT CELL FATE TRANSITIONS. THE RATIONALE OF OUR WORK IS THAT BY DECIPHERING HOW XPC REGULATES TDG-DEPENDENT DNA DEMETHYLATION IN RESPONSE TO HIF1A, WE WILL GAIN A NEW UNDERSTANDING OF HOW THE XPC-TDG-HIF1A AXIS INTEGRATES SIGNALS TO COORDINATELY REGULATE EPIGENETIC CHANGES THAT CONTRIBUTE TO NORMAL DEVELOPMENT AND REPROGRAMMING. THE CENTRAL HYPOTHESIS WILL BE TESTED BY PURSUING THREE SPECIFIC AIMS: 1) IDENTIFY MECHANISMS BY WHICH XPC-TDG-HIF1A AXIS REGULATES DNA DEMETHYLATION AND METABOLISM IN SOMATIC CELL REPROGRAMMING; 2) IDENTIFY MECHANISMS BY WHICH XPC PROMOTES RECRUITMENT OF TDG BY HIF1A; AND 3) IDENTIFY THE ROLE OF POST-TRANSLATIONAL MODIFICATIONS OF TDG VIA SUMOYLATION IN REGULATING DNA DEMETHYLATION DYNAMICS. UNDER THE FIRST AIM, GENOME-WIDE AND FUNCTIONAL STUDIES WILL BE EMPLOYED TO IDENTIFY HOW XPC AND TDG REGULATE EPIGENETIC CHANGES AT HIF1A-REGULATED GENE LOCI TO INDUCE TRANSCRIPTIONAL AND METABOLIC CHANGES FAVORABLE FOR REPROGRAMMING. IN THE SECOND AIM, BIOCHEMICAL AND LOSS-OF-FUNCTION STUDIES WILL BE PERFORMED TO IDENTIFY THE ROLE OF XPC AND NOVEL ASSOCIATING FACTORS IN DIRECTING TDG TO SPECIFIC GENE ENHANCERS FOR DEMETHYLATION. UNDER THE THIRD AIM, THE ROLE OF XPC IN REGULATING POST-TRANSLATIONAL MODIFICATIONS OF TDG AND THE EFFECT OF TDG SUMOYLATION ON DEMETHYLATION DYNAMICS AND SPECIFICITY WILL BE DIRECTLY MEASURED IN LIVING CELLS USING SINGLE PARTICLE TRACKING. THE PROPOSED RESEARCH IS INNOVATIVE BECAUSE NEW ACTIVITIES OF XPC IN DNA DEMETHYLATION, THROUGH POST-TRANSLATIONAL MODIFICATION OF TDG AND NOVEL TDG-HIF1A COMPLEX ASSEMBLY MECHANISM, WILL BE UNCOVERED USING NEW TOOLS. THIS CONTRIBUTION IS SIGNIFICANT, BECAUSE THE REGULATORY COMPONENTS AND EPIGENETIC MECHANISMS WE IDENTIFY ARE LIKELY TO ADVANCE OUR FUNDAMENTAL UNDERSTANDING OF EPIGENETIC CONTROL OF DEVELOPMENT, AND HOW EPIGENETIC DYSREGULATION CAUSES DISEASE.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $358.0k | 7/2/25 | ||
| Not listed | $358.0k | 7/10/24 |